<DOC>
	<DOCNO>NCT00756860</DOCNO>
	<brief_summary>The purpose study determine subject 2g AMG 223 achieve 60 % great reduction urinary phosphorus baseline compare subject 2g Renagel速 . Renagel速 , Sevelamer HCl currently market leader treatment hyperphosphatemia patient dialysis .</brief_summary>
	<brief_title>A Phase 1 Multiple Dose Study Compare Effects AMG 223 Sevelamer HCL ( Renagel速 )</brief_title>
	<detailed_description />
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Healthy nonsmoking men woman age 18 45 year , inclusive time consent . Healthy define absence clinically relevant abnormality , identify detailed medical history , complete physical examination , vital sign , 12 lead ECG , clinical laboratory test Screening randomization Females childbearing potential must nonlactating , must negative serum pregnancy test study enrollment , must use highly effective form contraception least 3 month study drug administration , study , additional 1 month study completion Male participant and/or partner must use highly effective form contraception sexual intercourse study additional 1 month study completion A body mass index ( BMI ) 18 30 kg/m2 , inclusive Serum phosphate within normal range Willing able provide write informed consent Willing able confined clinical research unit ( CRU ) require protocol Must abstain caffeine alcohol within 72 hour Day7 Day 7 inclusive . Evidence history clinically significant hematologic , renal , endocrinologic , pulmonary , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) judge relevant investigator History bowel obstruction , dysphagia , swallow disorder , gastrointestinal disorder inflammatory bowel disease , constipation , major gastrointestinal surgery , hemorrhoid , gastric/duodenal ulcer Unable unwilling swallow numerous capsules/tablets Known hypersensitivity Renagel速 constituent Having estimate glomerular filtration rate ( GFR ) &lt; 80 ml/ min ( Cockcroft Gault equation ) Blood donation &gt; 500 mL within 60 day Screening History alcohol abuse ( 14 alcoholic drink per week men 7 alcoholic drink per week woman ( one drink equal 12 oz beer , 8 oz wine , drink contain one ounce liquor ) use illicit drug within 12 month Screening Positive result follow test : Urine drug breath alcohol Screening Day 7 , Serum pregnancy test ( female ) Screening Day 7 , Human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HepCAb ) Screening Women pregnant , breastfeeding , plan become pregnant course study Participation another clinical trial investigational drug device within 30 day 5 half life investigational drug ( know ) , whichever longer , study drug administration Use prescription nonprescription drug ( herbal remedy , vitamin , nutraceuticals ) within 14 day 5 halflives , whichever longer , Day 7 study ( exclude acetaminophen dose 2 g/day hormonal birth control pill ) Use prescription nonprescription drug may affect gut motility within 14 day 5 halflives , whichever longer , Day 7 study Subject available followup assessment concern subject 's compliance protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>